Prior to survey, have you heard of RTD |
Yes |
31 |
(34.1) |
No |
60 |
(65.9) |
Missing/Unknown/No response |
0 |
(0.0) |
Rate your general knowledge of RTD |
None/limited |
71 |
(78.0) |
Somewhat/knowledgeable |
20 |
(22.0) |
Missing/Unknown/No response |
0 |
(0.0) |
Ethical or religious concerns about discussing RTD with a patient |
Yes |
4 |
(4.4) |
No |
87 |
(95.6) |
Missing/Unknown/No response |
0 |
(0.0) |
Comfortable discussing RTD with cancer patients |
Yes |
36 |
(40.0) |
No |
16 |
(17.8) |
Not sure |
38 |
(42.2) |
Missing/Unknown/No response |
1 |
|
Comfortable discussing RTD with a patient you are seeing for the first time |
Yes |
8 |
(8.8) |
No |
53 |
(58.2) |
Not sure |
30 |
(32.9) |
Missing/Unknown/No response |
0 |
(0.0) |
Is your decision to discuss RTD with a patient influenced by your current knowledge of the topic |
Yes |
51 |
(56.0) |
No |
15 |
(16.5) |
Not sure |
24 |
(26.4) |
Missing/Unknown/No response |
1 |
(1.1) |
Worries about RTD |
Emotional state of the patient following introduction of this topic |
65 |
(71.4) |
Ethical and legal issues related to informed consent |
6 |
(6.6) |
Ethical and legal issues related to the storage of human biological samples of deceased individuals |
2 |
(2.2) |
That the technologies can easily be used for the wrong purposes |
3 |
(3.3) |
Missing/Unknown/No response |
15 |
(16.5) |
Benefits about RTD |
Provides larger tumor samples |
13 |
(14.3) |
Allows sampling of multiple tumor sites (heterogeneity) |
23 |
(25.3) |
Allows testing on later stage or aggressive cancers (Stage III–IV) |
10 |
(11.0) |
Ability to reveal or confirm newer therapies/methods |
23 |
(25.3) |
Obtaining fresh tissue |
15 |
(16.5) |
Missing/Unknown/No response |
7 |
(7.7) |